BridgeBio Pharma Total Liabilities 2018-2024 | BBIO

BridgeBio Pharma total liabilities from 2018 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
BridgeBio Pharma Annual Total Liabilities
(Millions of US $)
2023 $1,889
2022 $1,866
2021 $1,880
2020 $597
2019 $158
2018 $88
2017 $0
BridgeBio Pharma Quarterly Total Liabilities
(Millions of US $)
2024-06-30 $1,876
2024-03-31 $1,887
2023-12-31 $1,889
2023-09-30 $1,850
2023-06-30 $1,854
2023-03-31 $1,839
2022-12-31 $1,866
2022-09-30 $1,857
2022-06-30 $1,876
2022-03-31 $1,854
2021-12-31 $1,880
2021-09-30 $1,520
2021-06-30 $1,539
2021-03-31 $1,483
2020-12-31 $597
2020-09-30 $572
2020-06-30 $580
2020-03-31 $541
2019-12-31 $158
2019-09-30 $119
2019-06-30 $0
2019-03-31 $0
2018-12-31
2018-09-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00